A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

252

Enrollment

INDUSTRY

Sponsor class

Conditions

Depressive Disorder, Treatment-Resistant

Interventions

DRUG: Esketamine 56 mg
DRUG: Esketamine 84 mg
DRUG: Placebo
DRUG: Duloxetine (Oral Antidepressant)
DRUG: Escitalopram (Oral Antidepressant)
DRUG: Sertraline (Oral Antidepressant)
DRUG: Venlafaxine Extended Release (XR) (Oral Antidepressant)

Sponsor

Janssen Research & Development, LLC